Claims for Patent: 8,535,670

Summary for Patent: 8,535,670

Title:	Method of treating colorectal cancer tumor
Abstract:	The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
Inventor(s):	Seshagiri; Somasekar (San Carlos, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	13/537,739
Patent Claims:	1. A method for treating an individual having a colorectal cancer tumor, comprising: (i) determining in a sample of said tumor that a KRAS protein mutation or a nucleic acid encoding a KRAS protein mutation is absent; (ii) selecting an EGFR inhibitor appropriate for the treatment of said tumor; and (iii) administering said EGFR inhibitor to the individual wherein said method comprises determining whether a mutation in codon 12 or 13 of the DNA encoding KRAS is absent; wherein said mutation in codon 12 or 13 encodes a G12A, G12C, G12R, G12S, G12V, G13C, or G13D mutation, wherein said sample of said tumor comprises an epidermal growth factor receptor. 2. The method of claim 1, wherein said EGFR inhibitor is cetuximab or panitumumab. 3. The method of claim 1, wherein determination of the absence of a nucleic acid encoding a KRAS protein mutation comprises contacting nucleic acid from said tumor sample with a nucleic acid probe that is capable of hybridizing to nucleic acid encoding a KRAS protein or fragment thereof, and detecting said hybridization. 4. The method of claim 1, wherein determination of the absence of a nucleic acid encoding a KRAS protein mutation in said tumor sample comprises sequencing DNA encoding a KRAS protein or a fragment thereof. 5. The method of claim 1, wherein said method further comprises administration of a chemotherapeutic agent.

Details for Patent 8,535,670

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2024-06-04
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2024-06-04
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2024-06-04